GLP-1 & MetabolicWell StudiedPhase 3 (Investigational)S

CBL-514

Investigational small-molecule injectable (not a peptide) · Selective adipocyte apoptosis (injectable lipolysis); local subcutaneous fat reduction — not GLP-1/GIP/glucagon receptor agonism

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts may use modeled aggregates when live snapshots are unavailable.

Read the CBL-514 explainerInvestigational small-molecule fat-reduction injection (not a peptide): Phase 3 program, trial data, and Kybella comparison.
Studies cited
16
Research grade
S
Experience
78

Overall check-ins

Activity
87

Trackers & reports

Typical Dose

Varies by protocol

Route

Injectable (subcutaneous, clinical trials)

Cycle

Clinical-trial only

Storage

Investigational study product

What is CBL-514?

CBL-514 is a Caliway Biopharmaceuticals small-molecule injectable in global Phase 3 (SUPREME program) for abdominal subcutaneous fat reduction. It is not a peptide and not a GLP-1 drug; company and published materials describe selective adipocyte apoptosis in treated tissue. Investigational only — not FDA-approved. Kybella (deoxycholic acid) remains the only FDA-approved injectable for localized fat, and only for submental fat. Online products labeled “CBL-514 peptide” are not the study drug.

Not a peptide. CBL-514 is a small-molecule investigational injectable. It is not FDA-approved. Anything sold online as "CBL-514 peptide" is not Caliway's study drug. Read the full explainer.

Mechanism of Action

Selective adipocyte apoptosis (injectable lipolysis); local subcutaneous fat reduction — not GLP-1/GIP/glucagon receptor agonism

Target: Adipocytes (localized subcutaneous fat)

Research / educational reference. Educational reference only — not medical advice. CBL-514 is investigational, not FDA-approved, and not a peptide. Community reports are not evidence of efficacy. Anything sold online as CBL-514 is not Caliway's study drug.

Evidence at a glance

Derived · maturity-1.0

Human efficacy for an approved label is unproven until regulators act on an NDA. Literature counts are bibliographic, not proof of cosmetic or metabolic outcomes.

Literature maturity

phase_3_candidate 42/100

PubMed hits

7

CT.gov trials

2

Strong-human apps

4

Sample papers

4

Sample articles by era

  • 2022-20264

Application grades (curated)

  • Human-grade apps4
  • Animal / in-vitro0
  • Mechanistic0

Does literature support studied applications?

Grades reflect cited literature posture — not a treatment recommendation. Community notes are never efficacy evidence.

ApplicationCited evidenceGradeCommunity
Abdominal subcutaneous fat reduction

Randomized phase 2/2b trials report subcutaneous volume and scale improvements vs placebo; global phase 3 SUPREME program underway.

NCT07140939NCT07526974PMID 40037659PMID 42159040

Limited human (Phase 2–3 ongoing)Not available outside clinical trials; not FDA-approved.
GLP-1 combination / weight-regain hypothesis

Company-reported rodent work with semaglutide or tirzepatide; Phase 2 combination IND cleared Aug 2026. Not a consumer stack.

Preclinical + early clinical planningDo not combine with prescription GLP-1s without trial or clinician supervision.
Dercum's disease (CBL-514D)

Phase 2a lipoma data published; pain endpoint reported in 2026 company release for CBL-0202DD.

PMID 41623934

Limited human (orphan path)Orphan indication; separate formulation from cosmetic abdominal program.

Pharmacology

Mechanism of action

  • •Described mechanism: selective induction of adipocyte apoptosis in injected subcutaneous fat, reducing adipocyte number locally.
  • •Not an incretin mimetic — does not replace GLP-1, GIP, or glucagon receptor pharmacology.

Identity & chemistry

Storage & stability

Lyophilized
N/A — investigational ready-to-use solution in trials
Reconstituted
N/A

Educational estimates. Prefer product labeling and peptide shelf-life tool.

Lab handling posture

Clinical-trial product only. This page is not handling guidance for consumers.

  • •CBL-514 is administered in registered trials under investigator supervision.
  • •Do not treat research-peptide vial workflows as equivalent.
  • •Unapproved online products are not the Caliway investigational drug.

Research Indications

Abdominal subcutaneous fat reductionEffective

Phase 2/2b RCTs report volume and scale improvements vs placebo; global SUPREME Phase 3 program ongoing (investigational).

Abdominal contour / appearanceModerate

Patient- and clinician-reported abdominal fat rating scales improved in phase 2b vs placebo in company-reported analyses.

Visceral adipose tissue (MRI substudies)Limited

Small subgroup MRI analyses at EASD 2026 suggested VAT changes; not an approved metabolic indication.

GLP-1 combination / weight regain (research)Limited

Preclinical combination data with GLP-1 drugs and an IND-cleared phase 2 combo trial; not consumer guidance.

Dercum's disease (CBL-514D)Limited

Separate orphan formulation; phase 2a lipoma data published; pain endpoint reported for CBL-0202DD.

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Investigational statusNo approved or public self-use scheduleClinical trials onlySubcutaneous (study sites)

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

GLP-1 receptor agonists (tirzepatide, semaglutide)Monitor
Deoxycholic acid (Kybella) in same treatment areaCaution
Other localized fat devices or injectablesCaution
Anticoagulants / bleeding disordersMonitor
MRI-incompatible implants or devicesCaution

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    CBL-514 is an investigational ready-to-use injectable used in registered clinical trials — not a lyophilized research peptide vial.

  2. 2

    Trial sites prepare and administer study drug under the protocol and investigator supervision.

  3. 3

    PeptIQ does not provide reconstitution, dosing, or self-injection instructions for CBL-514.

  4. 4

    Products sold online as "CBL-514" are not Caliway's investigational candidate and are not FDA-reviewed medicines.

What to Expect

During trial treatment

Multiple sequential injection sessions under protocol; injection-site reactions most common in published studies.

Post-treatment follow-up

Phase 2 programs measured outcomes weeks after the final session (e.g. 4–8 weeks); durability beyond those windows is not established.

With GLP-1 medicines

Only in registered combination trials — not a validated home stack.

If considering online listings

Unapproved products are not Caliway's investigational drug; avoid self-experimentation.

Side Effects & Safety

  • Investigational — not FDA-approved for any use
  • Injection-site pain, swelling, redness (most common in published phase 2 trials; mostly mild to moderate)
  • Transient local reactions; serious events not emphasized in published reports but phase 3 database is incomplete
  • Large-volume subcutaneous sessions in trials may not match cosmetic deoxycholic acid visits
  • MRI and protocol exclusions apply in studies (e.g. uncontrolled diabetes, coagulation disorders)
  • Anything sold online as "CBL-514 peptide" is not the Caliway study drug

CBL-514 is not FDA-approved and cannot be prepared by 503A compounding pharmacies. PeptIQ does not sell peptides or list vendors. Talk with a licensed clinician.

FDA Status & Regulatory Info

Phase 3 (Investigational)

CBL-514 is a Caliway Biopharmaceuticals small-molecule injectable in global Phase 3 (SUPREME program) for abdominal subcutaneous fat reduction. It is not a peptide and not a GLP-1 drug; company and published materials describe selective adipocyte apoptosis in treated tissue. Investigational only — not FDA-approved. Kybella (deoxycholic acid) remains the only FDA-approved injectable for localized fat, and only for submental fat. Online products labeled “CBL-514 peptide” are not the study drug.

Rx Required: Yes
503A Ban: Yes
Telehealth: No
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 1,416 users report

Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.

1416 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 60% · Mixed 32% · Unfavorable overall 8%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Digestive comfort
91
Skin appearance
111
Appetite control
136
Energy
95
Mood
44

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Flushing
187
Headache
191
GI discomfort
101
Dizziness
90
Fatigue
44

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 0–1000 mcg

0–10
2
10–25
6
25–50
11
50–100
17
100–200
28
200–400
19
400–600
11
600–1000
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing20stacking38side effects26cbl-51424

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 312 repeat reporters

Share Your Experience

Rate CBL-514 in the PeptIQ app and help the community make informed decisions.

Research References (12)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. PubMed

    Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study

    Gold M, Schlessinger J, Goodman GJ, et al. Aesthetic Surgery Journal. 2025

    Source
    Wiki study page →
  2. PubMed

    Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment

    Lorenc ZP, Gold M, Schlessinger J, et al. Aesthetic Surgery Journal. 2026

    Source
    Wiki study page →
  3. PubMed

    Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction

    Goodman GJ, Ho WWS, Chang KJ, et al. Aesthetic Surgery Journal. 2022

    Source
    Wiki study page →
  4. PubMed

    Efficacy and safety of CBL-514 for Dercum disease lipomas: A randomized phase 2a study

    Herbst KL, Ling YF, Sheu AY, et al. JAAD International. 2026

    Source
    Wiki study page →
  5. ClinicalTrials.gov

    SUPREME-01 (NCT07140939): Phase 3 CBL-514 for abdominal subcutaneous fat

    ClinicalTrials.gov. Clinical trial registry. 2026

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    SUPREME-02 (NCT07526974): Phase 3 CBL-514 for abdominal subcutaneous fat

    ClinicalTrials.gov. Clinical trial registry. 2026

    Source
    Wiki study page →
  7. Manufacturer

    Caliway Announces First Patient Dosed in Global Phase 3 SUPREME-01 Trial of CBL-514

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  8. Manufacturer

    Caliway Highlights Global Phase 3 Progress and GLP-1 Combination Strategy (Aug 31, 2026 Investor Conference)

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  9. Manufacturer

    Caliway Completes U.S. FDA IND Submission for SUPREME-02 Phase 3 Study of CBL-514

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  10. FDA Drug Label

    KYBELLA (deoxycholic acid) injection — Prescribing Information

    Allergan. FDA Drug Label. 2015

    Source
    Wiki study page →
  11. Review Article

    An experimental drug kills fat cells, rather than shrinking them

    Tina Hesman Saey, Science News. Science News. 2026

    Source
    Wiki study page →
  12. Review Article

    CBL-514 injection reduces visceral and subcutaneous fat in trials

    News-Medical.net. Conference news summary. 2026

    Source
    Wiki study page →

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your CBL-514 protocol in PeptIQ

Turn this CBL-514 guide into a living protocol — doses, vials, and history in one place.

Track CBL-514Open web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Target
Adipocytes (localized subcutaneous fat)
Route
Injectable (subcutaneous, clinical trials)
Availability
Pharmacy
Rx Required
Yes
503A Ban
Yes
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss CBL-514 with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ